Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Zynlonta

- PMLiVE

AbbVie adds to cancer portfolio with $9.8bn Stemcentrx deal

Continues to build its oncology business to lessen its reliance on Humira

Sanofi reception

Sanofi makes $9.3bn unsolicited bid for Medivation

Hopes to boost oncology business with fast-growing prostate cancer drug Xtandi

National Institute for Health and Care Excellence NICE logo

NICE changes tack on Sanofi’s prostate cancer drug Jevtana

Approves the therapy for NHS use after accepting undisclosed additional discount 

Bristol Myers Squibb logo

Opdivo boosts survival in head and neck cancer by 30%

Pivotal trial of BMS’ PD-1 inhibitor shows "significant benefit" in overall survival

- PMLiVE

NICE promises UK to lead Europe for cancer drug approvals

But industry says running the new CDF will present NICE with a ‘hugely challenging’ task

- PMLiVE

Focus on multiple myeloma treatment: Witnessing a transformation

Consultant David Cooney of Blue Latitude Health will take you through how that transformation has happened, and where the treatment of multiple myeloma is heading.

Blue Latitude Health

Bo Jesper Hansen to step down as chairman of Sobi

Håkan Björklund will be nominated as his replacement

Bristol Myers Squibb logo

Opdivo backed for two new uses by CHMP

Recommended for additional European approvals in kidney cancer and NSCLC

- PMLiVE

New UK Cancer Drugs Fund takes shape

NICE to manage access to cancer treatments from 1 July

Eli Lilly HQ

Lilly wins European approval for lung cancer drug Portrazza

First biologic licenced in EU as a first-line treatment for adults with NSCLC

- PMLiVE

Astellas: Ten years young

Ken Jones and Sef Kurstjens on the company's progress and plans

- PMLiVE

Roche and AZ claim FDA breakthrough status for new drugs

Designation could speed up development for Roche’s ocrelizumab and AZ’s durvalumab 

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links